IL309813A - Antisense oligonucleotide (aso) gene inhibition and treatment - Google Patents
Antisense oligonucleotide (aso) gene inhibition and treatmentInfo
- Publication number
- IL309813A IL309813A IL309813A IL30981323A IL309813A IL 309813 A IL309813 A IL 309813A IL 309813 A IL309813 A IL 309813A IL 30981323 A IL30981323 A IL 30981323A IL 309813 A IL309813 A IL 309813A
- Authority
- IL
- Israel
- Prior art keywords
- aso
- treatment
- antisense oligonucleotide
- gene inhibition
- inhibition
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- 239000000074 antisense oligonucleotide Substances 0.000 title 1
- 238000012230 antisense oligonucleotides Methods 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163222336P | 2021-07-15 | 2021-07-15 | |
US202163224362P | 2021-07-21 | 2021-07-21 | |
PCT/US2022/073668 WO2023288240A1 (en) | 2021-07-15 | 2022-07-13 | Antisense oligonucleotide (aso) gene inhibition and treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
IL309813A true IL309813A (en) | 2024-02-01 |
Family
ID=82850241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL309813A IL309813A (en) | 2021-07-15 | 2022-07-13 | Antisense oligonucleotide (aso) gene inhibition and treatment |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP4370133A1 (en) |
JP (1) | JP2024525837A (en) |
KR (1) | KR20240037996A (en) |
AU (1) | AU2022312494A1 (en) |
CA (1) | CA3224471A1 (en) |
IL (1) | IL309813A (en) |
MX (1) | MX2024000636A (en) |
WO (1) | WO2023288240A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024233248A2 (en) * | 2023-05-05 | 2024-11-14 | Vanda Pharmaceuticals Inc. | Antisense oligonucleotide (aso) gene inhibition and treatment |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014246667A1 (en) * | 2013-04-04 | 2015-11-19 | Olivia Newton-John Cancer Research Institute | Methods of treating diseases characterized by excessive Wnt signalling |
WO2017214463A1 (en) * | 2016-06-09 | 2017-12-14 | The Regents Of The University Of California | Compositions and methods for treating cancer and biomarkers to detect cancer stem cell reprogramming and progression |
-
2022
- 2022-07-13 AU AU2022312494A patent/AU2022312494A1/en active Pending
- 2022-07-13 JP JP2024502210A patent/JP2024525837A/en active Pending
- 2022-07-13 IL IL309813A patent/IL309813A/en unknown
- 2022-07-13 CA CA3224471A patent/CA3224471A1/en active Pending
- 2022-07-13 WO PCT/US2022/073668 patent/WO2023288240A1/en active Application Filing
- 2022-07-13 EP EP22753948.3A patent/EP4370133A1/en active Pending
- 2022-07-13 MX MX2024000636A patent/MX2024000636A/en unknown
- 2022-07-13 KR KR1020247004273A patent/KR20240037996A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2022312494A1 (en) | 2024-01-18 |
JP2024525837A (en) | 2024-07-12 |
CA3224471A1 (en) | 2023-01-19 |
WO2023288240A1 (en) | 2023-01-19 |
MX2024000636A (en) | 2024-02-06 |
AU2022312494A9 (en) | 2024-01-25 |
WO2023288240A9 (en) | 2023-02-23 |
KR20240037996A (en) | 2024-03-22 |
EP4370133A1 (en) | 2024-05-22 |
WO2023288240A8 (en) | 2023-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013086444A3 (en) | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna | |
IL274023A (en) | Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases | |
MX2021014868A (en) | OLIGONUCLEOTIDES AND METHODS OF USE FOR THE TREATMENT OF NEUROLOGICAL DISEASES. | |
MX358603B (en) | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene. | |
WO2010138806A3 (en) | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene | |
IL309813A (en) | Antisense oligonucleotide (aso) gene inhibition and treatment | |
IL288259A (en) | Modified gapmer oligonucleotides and methods of use | |
EP4069256A4 (en) | Antisense oligomers for treatment of conditions and diseases | |
MX2021009135A (en) | Oligonucleotides matching col7a1 exon 73 for epidermolysis bullosa therapy. | |
IL279692A (en) | Composition comprising antisense oligonucleotide and use thereof for treatment of duchenne muscular dystrophy | |
GB202003618D0 (en) | Gene Therapy | |
IL285867A (en) | Antisense oligomers for treatment of conditions and diseases | |
MX2017014855A (en) | Antisense oligonucleotides to treat dystrophic epidermolysis bullosa. | |
IL309445A (en) | Pikfyve antisense oligonucleotides | |
EP3384028A4 (en) | ANTISENSE OLIGONUCLEOTIDE (ASO) INHIBITORS DIRECTED AGAINST THE MONOCARBOXYLATE 4 CARRIER (MCT4) AS THERAPEUTIC AGENTS IN THE TREATMENT OF CANCER | |
IL307787A (en) | Antisense oligonucleotides and their use for treatment of neurodegenerative disorders | |
IL318200A (en) | Gene therapy for fam161a-associated retinopathies and other ciliopathies | |
IL306119A (en) | Gene therapy for treating beta-hemoglobinopathies | |
GB202300865D0 (en) | Delivery of oligonucleotides | |
IL287608A (en) | Intrathecal and intravenous combination gene therapy for the treatment of infantile batten disease | |
GB202003109D0 (en) | Gene therapy | |
GB202002202D0 (en) | Gene therapy | |
IL313660A (en) | Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas | |
GB202215198D0 (en) | Gene therapy treatment | |
WO2023245118A3 (en) | Treatment of ms4a4e related diseases and disorders |